Last reviewed · How we verify

COVID19 pneumonia requiring supplemental oxygen — Treatment Landscape & Competitive Intelligence

COVID19 pneumonia requiring supplemental oxygen (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating COVID19 pneumonia requiring supplemental oxygen, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Anakinra Kineret Biovitrum Ab Interleukin-1 Receptor Antagonist Interleukin-1 receptor, type I 2001-01-01
Kineret ANAKINRA Biovitrum Ab Interleukin-1 Receptor Antagonist [EPC] Interleukin-1 receptor, type I 2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Biovitrum Ab · 2 drugs in COVID19 pneumonia requiring supplemental oxygen

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in COVID19 pneumonia requiring supplemental oxygen:

Cite this brief

Drug Landscape (2026). COVID19 pneumonia requiring supplemental oxygen — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/covid19-pneumonia-requiring-supplemental-oxygen. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing